Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.

Neuro-oncology - 14 Mar 2023

Seyve Antoine, Dehais Caroline, Chinot Olivier, Djelad Apolline, Cohen-Moyal Elisabeth, Bronnimann Charlotte, Gourmelon Carole, Emery Evelyne, Colin Philippe, Boone Mathieu, Vauléon Elodie, Langlois Olivier, di Stefano Anna-Luisa, Seizeur Romuald, Ghiringhelli François, D'Hombres Anne, Feuvret Loic, Guyotat Jacques, Capelle Laurent, Carpentier Catherine, Garnier Louis, Honnorat Jérôme, Meyronet David, Mokhtari Karima, Figarella-Branger Dominique, Ducray François

Abstract excerpt

BACKGROUND: Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described. METHODS: We analyzed pseudoprogression characteristics and explored the possibility of pseudoprogression misdiagnosis in IDHmt HGG patients, treated with radiotherapy (RT) (with or without chemotherapy [CT]), included in the French POLA network....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Incidence

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35953421
DOI: 10.1093/neuonc/noac194
PMCID: PMC10013645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.PMID 35953421Read ↗

Pseudoprogression in high-grade glioma.Semantic proximity Read ↗

Is there pseudoprogression in secondary glioblastomas?Semantic proximity Read ↗

IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.Semantic proximity Read ↗

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.Semantic proximity Read ↗

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.Semantic proximity Read ↗

Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas.Semantic proximity Read ↗

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma PatientsSemantic proximity Read ↗

Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients.Semantic proximity Read ↗

Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma.Semantic proximity Read ↗

Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation statusSemantic proximity Read ↗

Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.Semantic proximity Read ↗

Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.